MAPK3 and cancer: SLIT2 promoted the migration of endothelial cells and promoted the angiogenic activity via the ROBO1-VEGFR2-ERK1/2 signaling pathway; current data showed that the SLIT/ROBO pathway could be a promising therapeutic target for cancer [19,20].